Amylyx Pharmaceuticals Inc AMLX.OQ AMLX.O is expected to show a fall in quarterly revenue when it reports results on February 24 (estimated) for the period ending December 31 2024
LSEG's mean analyst estimate for Amylyx Pharmaceuticals Inc is for a loss of 52 cents per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy," 3 "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Amylyx Pharmaceuticals Inc is $10.00, above its last closing price of $3.52.
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Sep. 30 2024 | -0.75 | -0.71 | -1.07 | Missed | -50.7 |
Jun. 30 2024 | -0.64 | -0.73 | -0.73 | Met | 0 |
Mar. 31 2024 | 0.02 | -0.01 | -0.12 | Missed | -1,900 |
Dec. 31 2023 | 0.24 | 0.23 | 0.07 | Missed | -69.3 |
Sep. 30 2023 | 0.43 | 0.44 | 0.30 | Missed | -31 |
Jun. 30 2023 | 0.08 | 0.10 | 0.31 | Beat | 210 |
Mar. 31 2023 | -0.23 | -0.24 | 0.02 | Beat | 108.3 |
Dec. 31 2022 | -0.82 | -0.82 | -0.65 | Beat | 20.7 |
This summary was machine generated February 21 at 14:25 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。